BioLife: Freeze media sales to grow as more biologics enter market

By Dan Stanton

- Last updated on GMT

Biologics on the rocks? BioLife Solutions looks to clients' biologics going from clinical to commercial manufacture to boost sales of its freeze media
Biologics on the rocks? BioLife Solutions looks to clients' biologics going from clinical to commercial manufacture to boost sales of its freeze media

Related tags Stem cell

Second quarter sales of cryopreservation media grew 14% but BioLife Solutions says it expects revenues to skyrocket as clients’ biologics move out of the clinical stage..

Biolife manufactures the CryoStor freeze media range containing Dimethyl sulfoxide (DMSO), a reagent that helps protect against damage from intracellular ice when freezing and thawing biologics, as well as thermal shippers for biopharmaceuticals.

For the second quarter 2014, sales from these core products reached $1.1m (€0.8m) - an increase of 14% over the same period - and were attributed to a growth in demand from regenerative medicine makers and cell suppliers.

The figures brought some relief to the company’s total sales which dropped 48% due to the loss of a manufacturing contract for an undisclosed organ preservation company.

CEO Mike Rice was optimistic product revenues would continue to increase as its clients biologics move out of the clinical stage and into commercial manufacture.

Currently, BioLife’s products are being used in more than 130 customer clinical trials, he told investors during a conference call yesterday. In October 2012 the number stood at around 50 and reached 100 trials in January this year.

“The average annual revenue for clinical indication should our customers receive marketing and regulatory approvals and commence large scale commercial manufacturing [could] be in the $500,000 to $2m range,”​ he said. “This is a really remarkable customer base, and represents significant revenue and profit upside for BioLife over the next several years.”

Earlier this year Parcell Laboratories adopted​ a cell-and-tissue freezing technology made by BioLife for use in clinical trials of its adult stem cell therapies, whilst in April Adaptimmune selected Biolife’s media​ for a T-Cell Receptor product.

Other key customers include Cellular Dynamics, B Lonza, Stem Cell Technologies, Triangle Research Labs and Quidel Diagnostic Hybrids, who use BioLife’s products to preserve frozen and fresh cells during shipment from suppliers to their customers, Rice told investors.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars